GE Healthcare will participate in Applied Health Innovation Consortium led by ACC. The consortium is objectified towards developing predictive analytics and advanced clinical decision support for cardiac patients.
The collaboration has followed the trial released by GE Healthcare on heart disease detection that integrated AI with low ejection fraction.has teamed with the American College of Cardiology, intending to bring artificial intelligence and digital technology in heart-related treatment and diagnostics. The consortium is an association of patient advocates, technology experts, academic leaders, and industry partners to transform healthcare digitally.
Additionally, besides focusing on improving healthcare through AI in valvular heart disease, coronary artery disease, and heart failure, the collaboration will address atrial fibrillation management.The partnership is aimed at identifying gaps, prioritize them, and move forward in specific ways. The partnership will focus on AI-driven services, including improved decision making, risk prediction, and interpretation of images.